Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.
暂无分享,去创建一个
Ton N Schumacher | Magali Michaut | Ji-Ying Song | Roderick L Beijersbergen | Lodewyk Wessels | Xinyao Huang | Oscar Krijgsman | T. Schumacher | L. Wessels | M. Michaut | R. Beijersbergen | O. Krijgsman | D. Peeper | C. Lieftink | Judith M. Müller | K. Kemper | Ji-Ying Song | C. Gerlach | Marjon A Smit | Patricia A Possik | Daniel S Peeper | Kristel Kemper | Cor Lieftink | M. Smit | Carmen Gerlach | Judith Müller | Marjon A. Smit | Juliana C N Kenski | Aida Shahrabi | Bram Gerritsen | P. Possik | Xinyao Huang | J. Kenski | A. Shahrabi | Bram Gerritsen
[1] Joost B. Beltman,et al. Heterogeneous Differentiation Patterns of Individual CD8+ T Cells , 2013, Science.
[2] J. Bartek,et al. Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. , 2006, Cancer research.
[3] D. Tuveson,et al. Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.
[4] A. Pinder,et al. A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress , 2013, Oncogene.
[5] J. Utikal,et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.
[6] Mohamed H. Sayegh,et al. Identification of cells initiating human melanomas , 2008, Nature.
[7] Sreenath V. Sharma,et al. Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". , 2010, Biochemical pharmacology.
[8] E. Fuchs,et al. RNAi screens in mice identify physiological regulators of oncogenic growth , 2013, Nature.
[9] J. Pouysségur,et al. Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.
[10] Kam Y. J. Zhang,et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.
[11] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[12] A. Giaccia,et al. Oxygen sensing and the DNA-damage response. , 2007, Current opinion in cell biology.
[13] Corbin E. Meacham,et al. In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression , 2009, Nature Genetics.
[14] A. Giaccia,et al. Hypoxic Conditions Atm Activation and Signaling Under , 2008 .
[15] Nicola J. Curtin,et al. DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.
[16] S. Morrison,et al. Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.
[17] Irving L. Weissman,et al. Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.
[18] Shuxia Zhao,et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.
[19] Brian Keith,et al. HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.
[20] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[21] M. Ellis,et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. , 2012, The Journal of clinical investigation.
[22] Todd R. Golub,et al. BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.
[23] Mark T. W. Ebbert,et al. A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer , 2012, Breast Cancer Research and Treatment.
[24] Ramon Arens,et al. Dissecting T cell lineage relationships by cellular barcoding , 2008, The Journal of experimental medicine.
[25] W. Kaelin. The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.
[26] E. Sausville,et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.
[27] G. McArthur,et al. Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.
[28] Michael B Atkins,et al. Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.
[29] T. Shlomi,et al. A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence , 2013, Nature.
[30] Jonathan Maybaum,et al. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. , 2010, Cancer research.
[31] H. Piwnica-Worms,et al. Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. , 2011, Trends in molecular medicine.
[32] Hong Wu,et al. mTOR is activated in the majority of malignant melanomas. , 2008, The Journal of investigative dermatology.
[33] A. Hauschild,et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.
[34] S. Morrison,et al. Efficient tumor formation by single human melanoma cells , 2008, Nature.
[35] Takashi Asai,et al. The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells , 2012, Molecular Cancer Therapeutics.
[36] W. Kaelin,et al. Gleevec: Prototype or Outlier? , 2004, Science's STKE.
[37] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[38] A. Harris,et al. Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. , 2003, Melanoma research.
[39] Alexander Roesch,et al. A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.
[40] C. Sawyers. Making progress through molecular attacks on cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.
[41] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[42] E. Hammond,et al. Targeting Hypoxic Cells through the DNA Damage Response , 2010, Clinical Cancer Research.
[43] M. Herlyn,et al. Microenvironmental influences in melanoma progression , 2007, Journal of cellular biochemistry.
[44] S. Morrison,et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.
[45] Dirk Schadendorf,et al. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .